Risk analysis for allergenicity of new food proteins – Criteria for risk management decisions

On 22 February 2018 a workshop for the ImpARAS COST Action (Cost action 1402, www.imparas.eu) was held in Brussels for 20 representatives from different food allergy stakeholder groups (risk assessors and risk managers (public, EFSA, FSA), allergic patient groups, food lawyers, Industry, scientific community).

The ImpARAS working group on risk assessment (WG4) has been investigating how risk assessment activities can be better aligned with risk management objectives, thereby providing better evidence to support safety and societal acceptance of those novel proteins.  During the workshop, a representatives from the European Commission presented on the risk management procedures for novel foods and members of WG4 presented their work surrounding risk assessment strategies, discrepancies and a possible path forward for advancements in the field.

Wider discussions were then held with the invited stakeholders on criteria for risk assessment decision making and the consequences of these criteria for risk management and method development. TNO contributed by organizing the workshop itself with Marloes van der Wal and Kitty Verhoeckx on behalf of the ImpARAS network. Ben Remington presented the WG4 paper drafted by Geert Houben “Defining the targets for the assessment of IgE-mediated allergenicity of new dietary sources of protein” and Marty Blom presented case studies of novel foods reviewed by the EFSA NDA panel and how these can be linked to the criteria for risk assessment decision making strategy.

Participants at the workshop agreed that zero risk is not possible and that further discussions surrounding acceptable risk and defined risk management criteria would be beneficial for all stakeholders.

All presentations of the meeting will be shared on the ImpARAS website and please contact us if you would like further information.

Ben Remington & Kitty Verhoeckx